Optimal CD34<sup>+</sup> Cell Dose in Autologous Peripheral-Blood Stem-Cell Transplantation
Authors: Orhan Sezer, Kurt Possinger, Bernd Metzner, Hans-Jochen Illiger, Mohammed Wattad, Wolfgang Heit, Harald Fuss, Wolfgang Schultze, Salvatore Siena, Roberta Schiavo, Andrea Sartore-Bianchi, Paolo Pedrazzoli
Journal: Journal of Clinical Oncology (2000)

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2000.18.18.3319 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 10986066 Optimal CD34+ Cell Dose in Autologous Peripheral-Blood Stem-Cell Transplantation Orhan SezerxOrhan SezerSearch for articles by this author , Kurt PossingerxKurt PossingerSearch for articles by this author , Bernd MetznerxBernd MetznerSearch for articles by this author , Hans-Jochen IlligerxHans-Jochen IlligerSearch for articles by this author , Mohammed WattadxMohammed WattadSearch for articles by this author , Wolfgang HeitxWolfgang HeitSearch for articles by this author , Harald FussxHarald FussSearch for articles by this author , Wolfgang SchultzexWolfgang SchultzeSearch for articles by this author Salvatore SienaxSalvatore SienaSearch for articles by this author , Roberta SchiavoxRoberta SchiavoSearch for articles by this author , Andrea Sartore-BianchixAndrea Sartore-BianchiSearch for articles by this author , Paolo PedrazzolixPaolo PedrazzoliSearch for articles by this author Show More Universitätsklinikum Charité Berlin, GermanyStädtische Kliniken Oldenburg Oldenburg, GermanyEvang. Krankenhaus Essen-Werden Essen-Werden, GermanyHumaine Klinikum Bad Saarow Bad Saarow, GermanyOspedale Niguarda Ca' Granda Milan, Italy https://doi.org/10.1200/JCO.2000.18.18.3319 First Page Full Text PDF Figures and Tables © 2000 by American Society of Clinical OncologyjcoJ Clin OncolJournal of Clinical OncologyJCO0732-183X1527-7755American Society of Clinical OncologyResponse18092000In Reply:In Table 4 of our review article entitled "Therapeutic Relevance of CD34+ Cell Dose in Blood Cell Transplantation for Cancer Therapy,"1 we clearly state that the dose of hematopoietic progenitor cells currently recommended in the clinic for autografting is ≥ 5 × 106 CD34+ cells/kg. However, a large body of clinical and experimental evidence induced us to state that the optimal dose is ≥ 8 × 106 CD34+ cells/kg. This evidence is discussed thoroughly in the article and comprises faster platelet rather than neutrophil recovery with increasing CD34+ cell dose, telomeric shortening occurring in the leukocytes of patients who receive bone marrow transplantation, and ascertainment that reconstitution of durable hematopoiesis capable of coping with increased demand (further chemotherapy and/or radiation therapy, infections, surgery) occurs after autografting of ≥ 8 × 106 CD34+ cells/kg.1In their letter, Sezer et al do not consider platelet and long-term hematopoietic recovery. Nevertheless, even for myeloid recovery, the conclusion based on their own results seems contradictory to us. In Fig 1, Sezer et al show that on day 9 after autografting, the probability of reaching 500 neutrophils/μL is approximately 65%, 70%, 90%, and 95% for patients autografted with less than 2, ≥ 2 to less than 5, ≥ 5 to less than 8, and ≥ 8 × 106 CD34+ cells/kg, respectively. Parallel data on platelet recovery are missing in the letter of Sezer et al. REFERENCE1. Siena S, Schiavo R, Pedrazzoli P, et al: Therapeutic relevance of CD34+ cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 18:: 1360,2000-1377, Link, Google Scholar